Stockreport

NRX Pharmaceuticals Inc (NRXP) Q3 2025 Earnings Call Highlights: Strategic Clinic Expansion and ... [Yahoo! Finance]

NRX Pharmaceuticals, Inc.  (NRXP) 
PDF Loss from Operations: $4 million for Q3 2025, compared to $3 million in Q3 2024. Research and Development Expenses: Increased by $800,000 to support FDA initiatives f [Read more]